[新型昂贵治疗方法的国家登记处] - Suppr

Suppr

超能文献

[National registry for a new and costly treatment].

作者信息

Uhlig Till, Nordvåg Bjørn-Yngvar

出版信息

Tidsskr Nor Laegeforen. 2008 Aug 14;128(15):1654.

PMID:18704130

Abstract

摘要

相似文献

[National registry for a new and costly treatment].

Tidsskr Nor Laegeforen. 2008 Aug 14;128(15):1654.

The Corrona US registry of rheumatic and autoimmune diseases.

Clin Exp Rheumatol. 2016 Sep-Oct;34(5 Suppl 101):S96-S99. Epub 2016 Oct 19.

Has the use of disease-modifying anti-rheumatic drugs changed as a consequence of controlled access to high-cost biological agents through the Pharmaceutical Benefits Scheme?

Intern Med J. 2007 Sep;37(9):601-6. doi: 10.1111/j.1445-5994.2007.01396.x. Epub 2007 Jun 2.

Effectiveness of biologics in rheumatology: improving the evidence base.

Rheumatology (Oxford). 2011 Sep;50 Suppl 4:iv1-2. doi: 10.1093/rheumatology/ker238.

[Biologicals are the first choice for RA treatment -- contra].

Dtsch Med Wochenschr. 2005 Aug 19;130(33):1901. doi: 10.1055/s-2005-871918.

[Salvage therapy and difficult treatment situations].

Z Rheumatol. 2016 Dec;75(10):954-955. doi: 10.1007/s00393-016-0226-8.

BIOBADASER, BIOBADAMERICA, and BIOBADADERM: safety registers sharing commonalities across diseases and countries.

Clin Exp Rheumatol. 2014 Sep-Oct;32(5 Suppl 85):S-163-7. Epub 2014 Oct 30.

The National Data Bank for rheumatic diseases: a multi-registry rheumatic disease data bank.

Rheumatology (Oxford). 2011 Jan;50(1):16-24. doi: 10.1093/rheumatology/keq155. Epub 2010 Jun 21.

[Solutions for off-label therapy].

Z Rheumatol. 2003;62(Suppl 2):II54-6. doi: 10.1007/s00393-003-1216-1.

[Do DMARDs contibute to impaired healing after surgery? Should they be discontinued before surgery?].

Dtsch Med Wochenschr. 2007 Sep;132(37):1901-4. doi: 10.1055/s-2007-985615.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

[National registry for a new and costly treatment].

作者信息

Uhlig Till, Nordvåg Bjørn-Yngvar

出版信息

Tidsskr Nor Laegeforen. 2008 Aug 14;128(15):1654.

PMID:18704130

Abstract

摘要

相似文献

[National registry for a new and costly treatment].

Tidsskr Nor Laegeforen. 2008 Aug 14;128(15):1654.

The Corrona US registry of rheumatic and autoimmune diseases.

Clin Exp Rheumatol. 2016 Sep-Oct;34(5 Suppl 101):S96-S99. Epub 2016 Oct 19.

Has the use of disease-modifying anti-rheumatic drugs changed as a consequence of controlled access to high-cost biological agents through the Pharmaceutical Benefits Scheme?

Intern Med J. 2007 Sep;37(9):601-6. doi: 10.1111/j.1445-5994.2007.01396.x. Epub 2007 Jun 2.

Effectiveness of biologics in rheumatology: improving the evidence base.

Rheumatology (Oxford). 2011 Sep;50 Suppl 4:iv1-2. doi: 10.1093/rheumatology/ker238.

[Biologicals are the first choice for RA treatment -- contra].

Dtsch Med Wochenschr. 2005 Aug 19;130(33):1901. doi: 10.1055/s-2005-871918.

[Salvage therapy and difficult treatment situations].

Z Rheumatol. 2016 Dec;75(10):954-955. doi: 10.1007/s00393-016-0226-8.

BIOBADASER, BIOBADAMERICA, and BIOBADADERM: safety registers sharing commonalities across diseases and countries.

Clin Exp Rheumatol. 2014 Sep-Oct;32(5 Suppl 85):S-163-7. Epub 2014 Oct 30.

The National Data Bank for rheumatic diseases: a multi-registry rheumatic disease data bank.

Rheumatology (Oxford). 2011 Jan;50(1):16-24. doi: 10.1093/rheumatology/keq155. Epub 2010 Jun 21.

[Solutions for off-label therapy].

Z Rheumatol. 2003;62(Suppl 2):II54-6. doi: 10.1007/s00393-003-1216-1.

[Do DMARDs contibute to impaired healing after surgery? Should they be discontinued before surgery?].

Dtsch Med Wochenschr. 2007 Sep;132(37):1901-4. doi: 10.1055/s-2007-985615.